Z

Zymeworks
D

ZYME

13.040
USD
0.15
(1.12%)
مغلق
حجم التداول
12,115
الربح لكل سهم
-2
العائد الربحي
-
P/E
-9
حجم السوق
975,972,345
أصول ذات صلة
A
ARCT
0.160
(1.18%)
13.770 USD
C
CRSP
0.455
(0.88%)
52.120 USD
I
INO
-0.71500
(-33.49%)
1.42000 USD
S
SLNO
0.290
(0.34%)
86.550 USD
V
VCEL
0.130
(0.31%)
41.600 USD
المزيد
الأخبار المقالات

العنوان: Zymeworks

القطاع: Healthcare
الصناعة: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.